lunedì, 9 settembre 2024

Notizie AIOM – anno XIV n. 605

15 Novembre 2016

FDA Grants Brentuximab Vedotin Breakthrough Designation in CTCL

Brentuximab vedotin has received an FDA breakthrough therapy designation for the treatment of patients with CD30-positive mycosis fungoides (MF) or primary cutaneous anaplastic large cell lymphoma (pcALCL) following at least 1 prior systemic therapy, according to Seattle ...
Leggi tutto

15 Novembre 2016

EC Approves Frontline Olaratumab for Soft Tissue Sarcoma

The European Commission has granted an accelerated approval to olaratumab in combination with doxorubicin as a frontline therapy for patients with advanced soft tissue sarcoma, making it the first new therapy for this indication in over 40 years.The decision, which was preceded ...
Leggi tutto

15 Novembre 2016

CHMP Issues Positive Opinion for Ofatumumab Combo in Relapsed CLL

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of ofatumumab in combination with fludarabine and cyclophosphamide as a treatment for patients with relapsed chronic lymphocytic leukemia (CLL), according to Genmab, which codevelops ...
Leggi tutto

15 Novembre 2016

FDA Approves Nivolumab for Head and Neck Cancer

The FDA has approved nivolumab for patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN) following progression on platinum-based therapy.The approval is based on the CheckMate-141 study, in which the median overall survival (OS) with ...
Leggi tutto

14 Novembre 2016

Research needs in breast cancer

New research questions emerge as medical needs continue to evolve and as we improve our understanding of cancer biology and treatment of malignancies. Although significant advances have been made in some areas of breast cancer research resulting in improvements in therapies ...
Leggi tutto

14 Novembre 2016

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

The inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) could potentially overcome or delay resistance to endocrine therapy in advanced breast cancer that is positive for hormone receptor (HR) and negative for human epidermal growth factor receptor 2 (HER2). In this ...
Leggi tutto

11 Novembre 2016

Association of Obesity-Related Metabolic Disruptions With Cancer Risk and Outcome

Over the past 40 years, the prevalence of obesity has increased epidemically worldwide, which raises significant concerns regarding public health and the associated economic burden. Obesity is a major risk factor for several conditions including cardiovascular disease and ...
Leggi tutto

11 Novembre 2016

Prescription of Prophylactic Antiemetic Drugs for Patients Receiving Chemotherapy With Minimal and Low Emetic Risk

The use of antiemetic drugs for patients receiving chemotherapy with low or minimal emetic risk has been recognized as a growing concern for health care costs and patients' welfare. Relatively few studies have examined antiemetic prophylaxis or treatment of emesis associated ...
Leggi tutto

11 Novembre 2016

Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study

Evidence from retrospective studies suggests that disease progression after first-line chemotherapy for metastatic non-small-cell lung cancer (NSCLC) occurs most often at sites of disease known to exist at baseline. However, the potential effect of aggressive local consolidative ...
Leggi tutto

11 Novembre 2016

Nuova web-app

Una web-app gratuita, in otto lingue, per computer, tablet e smartphone sul tumore del polmone è disponibile sul sito del Corriere della Sera in collaborazione con l'Associazione Italiana di Oncologia Medica (leggi e scarica). Strumento interattivo in due versioni, ...
Leggi tutto